Current Report Filing (8-k)
December 28 2020 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
December 18, 2020
iBio,
Inc.
(Exact name of registrant as specified
in charter)
Delaware
(State or other jurisdiction of incorporation)
001-35023
|
|
26-2797813
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
8800 HSC Parkway
Bryan, TX 77807
(Address of principal executive offices
and zip code)
(979) 446-0027
(Registrant’s telephone number
including area code)
(Former Name and Former Address)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
IBIO
|
NYSE American
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item
5.02.
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
Appointment
of President
On December 18,
2020, iBio, Inc. (the “Company”) appointed Tom Isett, the Company’s Chief Executive Officer and Chairman of the
Board to serve as its President.
Mr Isett, age
55, was appointed as Chief Executive Officer and Executive Co-Chair effective March 10, 2020. He was subsequently appointed
as Chair of the Board effective June 12, 2020. He has served as a member of the Board since April 2019. In 2015, Mr. Isett
founded both Commence Bio, Inc., a private, early stage developer of cellular immunotherapies, as well as i.e. Advising, LLC,
a management and strategy consulting firm that advised Fortune 500 companies, private equity firms, biotechnology companies, and
standard-setting organizations. Prior to 2015, he held leadership roles for bioprocess product and service businesses over his
25 combined years with GE, Lonza, and BD. Mr. Isett led a turnaround of the Core Microbiology diagnostic business at BD, and
then went on to become the founding Vice President of Becton Dickinson’s BD Advanced Bioprocessing business, which he led
from inception to over $60 million in revenues by 2009. While at Lonza from 2009 to 2012, he contributed to the rapid growth of
the cell & gene therapy CDMO as Head of Cell Processing Technologies. Subsequently, at GE Life Sciences, he accelerated
growth for the North American BioProcess business via the introduction of an integrated solutions strategy, along with new commercial
and operating mechanisms to improve business execution.
Appointment
of Chief Scientific Officer
On December 28,
2020, the Company announced the appointment of Dr. Martin B. Brenner to serve as the Company’s Chief Scientific Officer,
effective January 18, 2021.
Dr. Brenner has
a strong history of success heading drug discovery and development teams at several of the world’s leading pharmaceutical
companies, including AstraZeneca (“AstraZeneca”), Eli Lilly and Company (“Lilly”), Pfizer Inc.(“Pfizer”),
and Merck Research Laboratories (“Merck Research Labs”). Most recently, Dr. Brenner served as Senior Vice President,
Chief Scientific Officer of Pfenex Inc. from March 2019 until its acquisition by Ligand Pharmaceuticals Incorporated
in October 2020. From 2017 to 2018, Dr. Brenner served as Chief Scientific Officer at Recursion Pharmaceuticals, Inc., a biotechnology
company. From 2016 to 2017, Dr. Brenner served as Vice President and Head of Research and Early Development at Stoke Therapeutics,
Inc., a biotechnology company. From 2013 to 2016, Dr. Brenner served as Executive Director, Diabetes & NASH, and Chair
of Diabetes & NASH Early Discovery Unit at Merck Research Lab. From 2012 to 2013, Dr. Brenner served as Senior Director,
Head of Bioscience, CVMD at AstraZeneca . From 2009 to 2012, Dr. Brenner served as an Associate Research Fellow for the Diabetes
Prevention and Remission Group at Pfizer . From 2003 to 2009, Dr. Brenner served as Senior Research Scientist for the Diabetes
Drug Hunting Team at Lilly. Dr. Brenner holds a Ph.D. in Pharmacology from the Veterinary School of Hannover in Hannover,
Germany a DVM from Veterinary School of Ludwig-Maximilians-University in Munich, Germany.
|
Item
9.01.
|
Financial
Statements and Exhibits.
|
The following exhibits are filed with this
Current Report on Form 8-K:
Signatures
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
IBIO INC.
|
|
|
Date: December 28, 2020
|
By:
|
/s/ Thomas F. Isett
|
|
|
Name:
|
Thomas F. Isett
|
|
|
Title:
|
Chairman and Chief Executive Officer
|
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024